ARS Pharmaceuticals reported $26.2 million in U.S. neffy net product revenue for the second quarter of 2026, bringing year-to-date net product revenue to $43.7 million. The company said it is shifting from broad consumer advertising to targeted engagement with high-volume prescribers, a move expected to cut second-half 2026 cash-based SG&A and R&D expenses to between $100 million and $110 million, down more than 40% from the first half. ARS Pharma also announced the appointment of Meg Smith as Chief Commercial Officer effective August 17, 2026, and said its field sales expansion is complete, with efforts focused on prescribers representing 44% of the U.S. market opportunity. The company expects a path to cash flow breakeven by the end of 2027 and plans to report interim Phase 2b data for its chronic spontaneous urticaria program in the first quarter of 2027. Total second-quarter revenue was $33.7 million, including $7.4 million in supply revenue from partners, while net loss was $62.3 million, or $0.63 per share, and cash, cash equivalents, and short-term investments stood at $143.8 million as of June 30, 2026.
ARS Pharmaceuticals, IncReports Q2 neffy revenue and cost cuts, expects cash flow breakeven by end of 2027.
